Biotech Co. Pharma Co. Type/Product Area Amount Terms/Details (Date)
Affymetrix Inc. Novartis Institute for Functional Genomics (a unit of Novartis AG; Switzerland) GeneChip Array technology ND The agreement provides for volume-based pricing for GeneChip array purchases and a broad technical collaboration between Novartis Institute and Affymetrix scientists to develop new applications for GeneChip arrays; the Scripps Research Institute and the Novartis Agricultural Discovery Institute also have the option to gain broad access to GeneChip technology (9/99)
Amrad Corp. (Australia) Glaxo Wellcome Australia Ltd. (unit of Glaxo Wellcome plc) Oprol (sameterol xinafoate) for asthma ND Amrad co-markets product in Australia (2/99)
Aurora Biosciences Corp. Clontech Laboratories Inc. Mutant green fluorescent proteins ND Clontech to apply technology to not-for-profit customers worldwide for non-commercial research with a ¿zip-lock¿ license; Clontech may also supply to for-profit customers for non-commercial research (direct license required from Aurora); Clontech pays up-front technology access fee and royalties on sales (3/99)
Aurora Biosciences Inc. Pfizer Inc. Technology access agreement; Aurora will provide automated systems (including those for compound storage, high-throughput screening and multiple ion channel lead discovery platforms) at Pfizer research facilities worldwide $50M Contract includes $50M in guaranteed payments, plus milestones, profit sharing for commercialized compounds identified using the system, and funding related to the exercise of various options included in the deal (6/99)
Avanir Pharmaceuticals SmithKline Beecham plc Docosanol 10% cream in the over-the-counter market for treatment of recurrent oral-facial herpes ND SmithKline signed letter of intent for rights to market docosonal 10% over the counter (12/99)
AVAX Technologies Inc. Neptunus International Holdings Ltd. (Australia) M-Vax, an autologous cancer vaccine for melanoma A$4M (US$2.5M) Companies created joint venture, AVAX Australia Pty. Ltd., to manufacture and market M-Vax in Australia, with similar rights for New Zealand AVAX Australia received A$4M from Neptunus for a 20% stake in the joint venture; Neptunus has an option to purchase an additional 30% interest for A$6M; AVAX has also been granted options to purchase common stock equivalent to 5% of Neptunus' shares (12/99)
BioFocus plc (UK) Glaxo Wellcome SpA (Italy) Undisclosed compounds ND BioFocus will produce high quality, exclusive compounds for Glaxo's drug discovery programs using its SoftFocus range of screening libraries (10/99)
Centocor Inc. Covance Retavase (recombinantreteplase) ND Covance to manufacture product for U.S. and Canada; further terms ND (4/99)
Centocor Inc. Pharmacia & Upjohn Fragmin (dalteperin sodium for injection) ND Centocor to promote product in U.S. after FDA approval; further details ND (3/99)
Centocor Inc. Covance Long-term manufacturing agreement under which Covance will produce Centocor's Retavase for the U.S. and Canadian markets ND ND (4/99)
Cephalon Inc. Abbott Laboratories Collaborative agreement to further develop and market Abbott's Gabitril, an antiepileptic drug, in the U.S.; Abbott gains a right of first negotiation to develop and promote Cephalon's Provigil (an FDA-approved narcolepsy drug) should Cephalon elect to collaborate with a 3rd party in the U.S. ND Cephalon is required to make certain promotional and clinical development expenditures, and will share in growth of the product sales beyond a contractually specified baseline; Abbott has a right of first negotiation to develop and promote Cephalon's Provigil in the U.S. (6/99)
Cephalon Inc. H. Lundbeck A/S (Denmark) Development and marketing agreement for Cephalon's preclinical-stage receptor tyrosine kinase inhibitors $40M Cephalon will receive aproximately $40M, which includes an up-front license fee, research and milestone payments, and an equity investment of $12M (1M Cephalon shares at $12 each); Lundbeck will also share development costs and support research; Lundbeck gains commercial rights in Europe and certain other territories (6/99)
Corvas International Inc. Covance Biotechnology Services Inc. rNAPc2 ND Corvas entered an agreement with Covance for the manufacture of rNAPc2 for Phase III testing in patients undergoing unilateral, total knee replacement; financial details ND (8/99)
Cypress Bioscience Inc. Fresenius AG (Germany) Prosorba column for rheumatoid arthritis ND Letter of intent for exclusive license and distribution agreement covering U.S., Europe, Latin America and, subject to certain conditions, Japan; Fresenius to have exclusive rights outside the U.S., where product will be jointly introduced (1/99)
Cypress Bioscience Inc. Fresenius AG (Germany) Fresenius exercised option to acquire manufacturing rights for Cypress' Prosorba column for treating rheumatoid arthritis $5.2M Fresenius gained the option as part of marketing alliance signed 3/99; the $4M Cypress had drawn down from a line of credit will be applied to the purchase price of the facility, and Fresenius paid an additional $1.2M to exercise the purchase option (4/99)
Cypress Bioscience Inc. Meduxus Inc. (Canada) Prosorba column therapy for rheumatoid arthritis ND Meduxus will apply for approval in Canada and will market and distribute the product; Cypress will get the lesser of a predetermined percentage of net Canadian sales or a transfer price (12/99)
CytRx Corp. Nycomed Inc. Flocor, purified poloxamer 188 ND Nycomed will perform purification, testing and release of purified poloxamer 188 in accordance with CytRx specifications and procedures, as well as perform equipment and process validations and assist with regulatory interactions; financial details ND (9/99)
DiagnoCure Inc. (Canada) Medite Histotechnic Italia (Italy) Distribution agreement under which Medite will distribute in Italy DiagnoCure's ImmunoCyt diagnostic test for the detection of superficial bladder cancer using (monoclonal antibodies) ND ND (3/99)
DiagnoCure Inc. (Canada) Euro-Diagnostica AB (Sweden) Distribution agreement under which Euro-Diagnostica will distribute ImmunoCyt's monoclonal antibody-based diagnostic test for superficial bladder cancer in Sweden, Norway, Denmark and Finland ND ND (5/99)
Digene Corp. Abbott Laboratories Sales and marketing agreeagreement under which Abbott will handle those responsibilities for Digene's women's health and blood virus DNA testing products in Europe, the Middle East and Africa; agreement replaces Digene's agreement with International Murex Technologies Corp., which Abbott acquired in 1998 ND ND (5/99)
Draxis Health Inc. (Canada) Elan Corp. plc (Ireland) Draxis licensed from Elan exclusive Canadian rights to 8 neurology products, of which 3 are approved, 3 are nearing approval and 2 are late-stage; products include Zanaflex (tizanidine hydrochloride; approved) Diastat (diazepam rectal gel; approved), Mysoline (primidone; approved), frovatriptan, NeuroBloc (botulinum toxin type B), ziconotide, Zonegran (zonisamide) and Zelapar (selegiline hydrochloride flashtab) Elan to receive $12M, but will pur chase $8M in Draxis equity Draxis will pay Elan a 1-time up-front fee of $12M; Elan will purchase 3.04M treasury shares of Draxis at a price per share of $2.63 ($8M total), a premium to trading price, representing a stake of 8.6%; Everen Securities acted as financial advisor to Draxis; Elan will supply manufactured products to Draxis and provide assistance with pricing and regulatory and launch activities; agreement expires 12/31/98 (6/99)
Duramed Pharmaceuticals Inc. Solvay Pharmaceuticals Inc. Cenestin tablets, Estratest/ Estratest H.S. tablets and Prometrium capsules ND The companies entered an alliance to jointly market three of their hormone therapies in the U.S.; Duramed will give Solvay an option to purchase a minimum of 1.6M shares and a maximum of 3M shares of common stock at $9 per share (10/99)
DUSA Pharmaceuticals Inc. Schering AG (Germany) Levulan (aminolevulinic acid HCl) $23.75M Schering gains exclusive worldwide marketing and distribution rights worldwide (except Canada) for dermatology indications; DUSA will receive milestones and other payments upon signing, regulatory approval and first commercial sale, plus a $6.25M equity investment; agreement also includes research funding by Schering on new dermatology indications and pre-paid royalties following FDA approval of up to 3 additional dermatology indications; for product supply, DUSA will receive a combined royalty/supply fee based on sales (11/99)
EntreMed Inc. Covance Biotechnology Services Angiostatin protein for anti-angiogenesis ND Covance to provide large-scale GMP production of Angiostatin for further preclinical studies (3/99)
EntreMed Inc. Chiron Corp. Bulk production of EntreMed's anti-angiogenic protein, Endostatin ND Companies signed letter of understanding that Chiron will perform contract manufacturing of bulk Endostatin protein (12/99)
Enzo Biochem Inc. NEN Life Science Products Inc. Various products; reagents; DNA labeling technologies ND NEN to distribute products globally; further details ND (1/99)
Epitope Inc. Organon Teknika Ltd. (subsidiary of Akzo Nobel; the Netherlands) Organon will collaborate on final development of OraQuick (an oral fluid rapid assay test for HIV infection) and will manufacture initial pre-production lots ND If product succeeds in winning approvals, companies plan to negotiate a long-term manufacturing and supply agreement (4/99)
FibroGen Inc. Zeneca LifeScience Molecules (business unit of Zeneca Group; UK) Recombinant collagen ND Zeneca to provide process development and scale-up expertise for commercialization of multi-gene expression technology; further details ND (3/99)
GelTex Pharmaceuticals Inc. Sankyo Pharma Inc. (Japan) and Sankyo ParkeDavis (5050 joint venture with ParkeDavis unit of Warner-Lambert Co.) Licensing and option agreement/Cholestagel (colesevelam hydro chloride), an NDA-stage product for the treatof hypercholesterolemia, as well as more potent second-generation product, GT 102279 $75M Sankyo will pay up to $75M, including $45M in up-front payments and milestones and $30M in funding for development of GT102-279; Sankyo receives exclusive marketing rights in the U.S. for Cholestagel for the treatment of high cholesterol and purchased an option for global rights to GT102-207; additional fees and milestones possible for GT102-207; Sankyo will also pay all development costs for second-generation compound while option is in effect; GelTex will receive royalties on all sales (11/99)
GeneFormatics Inc. Rikei Corp. (Japan) Data-mining technology ND Rikei will invest in GeneFormatics data-mining technology and will serve as the exclusive sales and marketing channel for the company's products and services in Japan (12/99)
Gensia Sicor Inc. Abbott Laboratories Inc. Oncology products portfolio ND Abbott to market and distribute multi-source oncology products now under development; further terms ND (1/99)
Genzyme Corp. Fresenius AG (Germany) Sepra products; adhesion barrier and coating solution ND Fresenius to distribute and market products in France, Germany, Australia, Switzerland and Luxembourg; further details ND (1/99)
Geron Corp. Clontech Laboratories Inc. Cell lines immortalized with telomerase enzyme ND Clontech to produce and sell products for the not-for-profit research market, and supply to biotechnology and pharmaceutical industries under licenses between Geron and the companies; Clontech gets up-front licensing fee; companies to share equally the operating profits from cell-line sales (3/99)
Hemispherx Biopharma Inc. Schering-Plough Corp. Ampligen, an antiviral under development for various diseases ND Schering-Plough will manufacture U.S. supplies of the drug at its facilities in San Juan, Puerto Rico; agreement may be expanded to include other territories (12/99)
IDEC Pharmaceuticals Inc. Schering AG (Germany) Marketing and distribution agreement for IDEC's Zevalin (Ibritumomab Tiuxetan; formerly called IDECY2B8), an anticancer monoclonal antibody conjugated to yttrium-90; product is in development as therapy for low-grade and/or follicular non-Hodgkin's B-cell lymphoma $47.5M Schering will pay IDEC $13M as an up-front licensing fee and will provide $15M in committed funding for Zevalin; IDEC may receive up to $19.5M in additional milestones, plus a royalty on sales outside the U.S.; Schering gains exclusive marketing rights outside the U.S.; IDEC retains U.S. rights (6/99)
InSite Vision Inc. Global Damon Pharm (Korea) AquaSite treatment for dry eye ND Global Damon to distribute AquaSite in Korea for 10 years, paying royalties to InSite; further terms ND (3/99)
Integra LifeSciences Corp. Healthpoint Ltd. Panafil for healing and debridement, and Accuzyme (enzymatic debridement agent used to remove necrotic tissue of wounds) ND Series of agreements to purchase Panafil product line, brand name and related equipment for $6.4M; Healthpoint also agreed to pay sales commissions to Integra for marketing Panafil and Accuzyme to the podiatry market and for marketing Panafil to certain hospitals with burn centers; Healthpoint will be responsible for all product distribution and coordination, and sales of both products in other markets (1/99)
Interneuron Pharmaceuticals Inc. Madaus AG (Germany) Trospium chloride, a prescription drug currently marketed as a treatment for urinary incontinence ND Interneuron gains exclusive U.S. marketing rights in exchange for milestones and royalties; Interneuron is responsible for all clinical development and regulatory activities and costs related to the compound in the U.S. (11/99)
Isis Pharmaceuticals Inc. Abbott Laboratories Isis 2302, an oligonucleotide antisense inhibitor of ICAM-1 ND Abbott will design and build a new manufacturing facility at its North Chicago, Ill., location; Abbott's process development team will lead a joint technical program aimed at optimizing efficiency, scale and costs in collaboration with Isis' proprietary oligonucleotide manufacturing technology; financial details ND (9/99)
LeukoSite Inc. and Ilex Oncology Inc. Schering AG (Germany) and Berlex Laboratories Inc. (a subsidiary of Schering AG) Campath, a humanized monoclonal antibody 30 Schering obtained exclusive marketing and distribution rights to Campath in the U.S., Europe and the rest of the world, excluding Japan and East Asia; in the U.S., Schering's subsidiary, Berlex, LeukoSite and Ilex will share profits from the sale of Campath; on sales made in the rest of the territory, Schering will pay royalties equivalent to the rate of profit sharing expected in the U.S.; Schering will make payments of up to $30M for rights to Campath and for the achievement of certain regulatory milestones (8/99)
LifeCell Corp. Boston Scientific Corp. Acellular tissue matrix for urology, gynecology procedures ND Boston Scientific to distribute product worldwide; LifeCell to pay distribution fee based on percentage of sales; funding to market development programs to be shared equally; joint oversight of clinical research and marketing programs (3/99)
Ligand Pharmaceuticals Inc. Ferrer Internacional SA (Spain) Oncology products ONTAK, Panretin gel and capsules, Targretin gel and capsules ND Ferrer to market and distribute products in Spain, Portugal, Greece and Central and South America; Ferrer has exclusive rights for 10 years, subject to extension; Ligand gets $2.5M over next six months as registration services reimbursement, plus milestone payment on first registration of Targretin for breast cancer in any of its European markets; Ligand to exclusively supply Ferrer with all 5 products for marketing in the territories (3/99)
The Liposome Co. Wyeth-Ayerst International (a subsidiary of American Home Products) Abelcet (lipid-based formulation of amphotericin B) ND Wyeth-Ayerst to market product in the UK; certain members of Liposome's UK sales force to join Wyeth-Ayerst's (3/99)
LJL Biosystems Inc. Sumitomo Corp. (Japan) Drug-discovery products ND Sumitomo to exclusively sell products in Japan; further details ND (2/99)
Martek Biosciences Corp. Amersham Pharmacia Biotech Ltd. (Sweden) PBXL fluorescent dye products for assays ND Pharmacia to supply products for market; further details ND (3/99)
Maxim Pharmaceuticals Inc. F.H. Faulding & Co. Ltd. (Australia) Marketing agreement for Maxim's Maxamine anticancer therapy in Australia and New Zealand ND Faulding will pay marketing rights fees and milestones, and provide clinical and regulatory assistance; Faulding will assume responsibility for registration and marketing approval and related applications for reimbursment in Australia and New Zealand; combined with agreement for Israel (see below), Maxim expects to receive a 40% or greater share of Maxamine sales within these territories (5/99)
Maxim Pharmaceuticals Inc. MegaPharm Ltd. (Israel) Marketing agreement for Maxim's Maxamine anticancer therapy in Israel ND As part of the agreement, MegaPharm will manage the Israeli component of 3 clinical trials and also will assume responsibility for approval application in Israel; combined with agreement for Australia and New Zealand (see above), Maxim expects to receive a 40% or greater share of Maxamine sales within these territories (5/99)
MGI Pharma Inc. Connetics Corp. Ridaura (auranofin), antirheumatic drug; Luxiq (betamethasone balerate) ND MGI to promote products in U.S. in exchange for promotional fees; for Ridaura, MGI gets $0.25M per quarter for making a certain number of sales calls, plus split of gross profits over first $7.5M; for Luxiq, MGI gets split of profits from sales in rheumatology market; Connetics retains profits from dermatology sales (3/99)
MitoKor Inc. SRL Inc. (Japan) MitoLoad assay and software to diagnose Alzheimer's disease ND SRL acquires right to use product for diagnosing Alzheimer's disease and selecting candidates for clinical trials; SRL pays up-front payment and royalties on a pertest basis; further terms ND (2/99)
Molecular Simulations Inc. (wholly owned subsidiary of Pharmacoepia Inc.) Ryoka Systems Inc. (wholly owned subsidiary of Mitsubishi Chemical Ltd.; Japan) Software products ND Ryoka exclusively distributes products to MSI customers in Japan, and commits to certain increased revenue levels for 24 months (3/99)
Neoprobe Corp. KOL Bio-Medical Instruments Inc. Gamma-guided surgery products ND KOL will market and promote Neoprobe's current and future products in the U.S.; further terms ND (3/99)
Neose Technologies Inc. McNeil Specialty Products Co. (a unit of Johnson & Johnson) Undisclosed complex carbohydrates ND The companies have formed a joint venture for the production of bioactive carbohydrates identical to plant-derived carbohydrates; the new venture replaces and expands the previous research and development agreement between the two companies; McNeil and Neose expect to share revenue and profits equally; further details ND (10/99)
Neuro-Biotech (Canada) Tutimpex Trading Co. Diagnostic kits for stressrelated and neurosciencerelated conditions ND Tutimpex to commercialize products in the Middle East; further details ND (3/99)
Onyx Pharmaceuticals Inc. Warner-Lambert Co. Onyx-015, an anticancer therapeutic $155M Onyx and Warner will jointly develop and commercialize Onyx-015, in addition to two new armed anticancer viruses; the companies will co-promote the three products in the U.S. and Canada, and will share equally in resulting profits; Warner will commercialize the products in the rest of the world and will pay Onyx a royalty on net sales; Warner will make an up-front payment and equity investment of $15M over the next two years, and will also provide $40M for Phase III trials and ongoing clinical development; in addition to the committed funding, Onyx could receive up to $100M upon achieving certain milestones (10/99)
Orphan Medical Inc. Pierre Fabre Medicament (France) Busulfex injection ND Pierre Fabre will receive exclusive marketing and distribution rights to Busulfex injection in 21 European countries, Argentina and South Africa; financial details ND (10/99)
Palatin Technologies Inc. Mallinckrodt Inc. Worldwide marketing agreement (excluding Europe) for Palatin's LeuTech radiolabeled infection imaging agent $23M ($13M equity purchase) Mallinckrodt gains exclusive worldwide license (excluding Europe) for sales, marketing and distribution of LeuTech products; Palatin will receive milestone payments, funding for 50% of development and clinical testing expenses for all indications covered in the agreement, a transfer price for LeuTech sales to Mallinckrodt and a royalty on sales; Mallinckrodt will purchase $13M worth of restricted, unregistered convertible preferred shares, which are convertible after 5 years to 0.7M common shares; milestones include $5M upon FDA marketing clearance and $5M when Mallinckrodt's LeuTech sales reach $20M (5/99)
PathoGenesis Corp. Swedish Orphan AB Distribution agreement for PathoGenesis' TOBI (tobramycin solution for inhalation) in Sweden, Denmark, Norway and Finland; drug is currently under review in the UK, the lead country for seeking approval in the European Union ND ND (5/99)
PathoGenesis Corp. PulmoPharm (Germany) PulmoPharm will market PathoGenesis' TOBI (tobramycin for inhalation) for cystic fibrosis in Germany upon the drug's approval ND PathoGenesis purchased equity amounting to 20 percent of PulmoPharm at an undisclosed price (5/99)
PathoGenesis Corp. AMRAD Pharmaceuticals Pty. Ltd. (Australia) TOBI (tobramycin solution for inhalation), an antibiotic for cystic fibrosisrelated infections ND AMRAD will distribute TOBI upon regulatory approval in Australia; financial details ND (11/99)
PathoGenesis Ltd. (affiliate of PathoGenesis Corp.) Genesis Pharma SA (member of MSJ Group; Greece) TOBI (tobramycin solution for inhalation), an antibiotic for cystic fibrosisrelated infections ND Genesis gains distribution rights in Greece and Cyprus upon approval in those countries; financial details ND (11/99)
Pharming Group N.V. (the Netherlands) DSM Biologics (the Netherlands) Recombinant human lactoferrin ND Pharming and DSM signed an agreement for the purification of recombinant human lactoferrin from the milk of transgenic cows; further details ND (9/99)
Procyte Corp. Merck KgaA (Germany) Iamin Hydrating Gel and other wound care products ND Merck to market lamin and other wound-care products in its Latin American regions (1/99)
Procyte Corp. Sigmacon Medical Products (Canada) Graftcyte, Complex Cu3 for skin repair, Tricomin for thinning hair, and other physician label products ND Sigmacon to market products in dermatology, cosmetic and surgery markets in Canada; further terms ND (3/99)
QLT Phototherapeutics Inc. Raylo Chemicals Inc. (Canada); Nippon Fine Chemical Co. (Japan); Parkedale Pharmaceuticals Inc. (wholly owned subsidiary of King Pharmaceuticals Inc.) Visudyne (verteporfin) for ophthalmic conditions ND Raylo to manufacture active ingredient; Nippon to manufacture formulated intermediate; Parkedale to manufacture finished, lypholized product; further terms ND (3/99)
SangStat Medical Corp. Abbott Laboratories Co-promotion, distribution and research agreement for SangStat's SangCya (cyclosporine oral solution; FDAapproved) in the U.S. $14M (equity purchase) Partnership marks continuation of initial agreement for Abbott to provide bulk cyclosporine to SangStat; Abbott will make a $14M equity purchase in SangStat, make up-front and milestone payments, and will make a long-term loan to SangStat (5/99)
SciClone Pharmaceuticals Sigma-Tau SpA (Italy) Sigma-Tau will market SciClone's Zadaxin thymosin alpha 1 for treatment of cancer and hepatitis in Italy, Spain and Switzerland ND Sigma-Tau receives semiexclusive development and marketing rights in Italy and Spain, and exclusive rights in Switzerland; Sigma-Tau will be responsible for clinical development and regulatory submissions in Italy (4/99)
Sepracor Inc. Abbott Laboratories Xopenex (levalbuterol HCl), a beta agonist for treatment of reversible bronchospasm ND Abbott's Ross Products Division will promote Xopenex to the pediatric market in the U.S.; Sepracor will be credited with all sales and Abbott will receive a commission on pediatric sales; each company is responsible for its own selling expenses (11/99)
Seragen Inc. (a subsidiary of Ligand Pharmaceuticals Inc.) F. Hoffmann-La Roche Ltd. (Switzerland) and its U.S. subsidiary, Hoffmann-La Roche Inc. Products containing the active ingredient daclizumab $2.5M Seragen entered a non-exclusive sublicense agreement with U.S.and Switzerland-based Roche with respect to Seragen's rights under the Strom patents family; Roche receives the right to make, use and sell in the U.S., Canada, Australia and New Zealand any product containing the active ingredient daclizumab, including Zenapax, a product Roche currently markets; Seragen will receive a $2.5M royalty for previous sales of Zenapax, plus royalties on net sales of licensed products in the U.S., Canada, Australia and New Zealand; Seragen will also receive milestone payments in the event Roche receives U.S. regulatory approval of licensed products containing daclizumab for the treatment of autoimmune indications (9/99)
SuperGen Inc. Abbott Laboratories Sales and marketing agreement/deal covers rubitecan, an oral chemotherapy compound in the camptothecin class currently in Phase III trials, and Nipent, which is already approved for hairy cell leukemia $150M Abbott will make an up-front equity investment of between $25M and $40M, plus additional milestones that bring the total to $150M, plus royalties and U.S. profit sharing; Abbott gains exclusive distribution and promotion rights to rubitecan outside the U.S. and co-promotion rights within; Abbott will also become exclusive U.S. distributor for Nipent (SuperGen retains marketing rights for the product) (12/99)
Synapse Technologies Inc. (Canada) Kyowa Medex Co. (Japan) p97 diagnostic assay for Alzheimer's disease ND Kyowa provided Synapse with up-front and pre-launch milestone payments exceeding C$2.5M, in exchange for exclusive promotion rights in Japan (3/99)
Synsorb Biotech Inc. (Canada) Paladin Labs Inc. Synsorb Cd, a therapeutic for the recurrent form of Clostridium difficile-associated diarrhea ND Paladin received exclusive marketing and distribution rights for Synsorb Cd; the companies will share equally in future revenues from Canadian sales; Synsorb will continue development of the product, and will manufacture and supply it to Paladin; Paladin will be responsible for all aspects of the marketing and sale of the product in Canada; financial details ND (9/99)
Triangle Pharmaceuticals Inc. Abbott Laboratories Marketing agreement for 6 antiviral products, 4 from Triangle and 2 from Abbott; Triangle products are Coviracil (for HIV and hepatitis B virus), Coactinon (formerly MKC-442; for HIV), DAPD (for HIV) and L-FMAU (for HBV) $335M ($118M equity) In the U.S., Abbott and Triangle will co-promote 4 Triangle products currently in development for HIV and hepatitis B virus, and Abbott's 2 HIV protease inhibitors (Norvir, which is FDA-approved, and Phase III-stage ABT-378); outside the U.S., Abbott will have exclusive sales and marketing rights for the 4 Triangle antivirals; Abbott will purchase 6.57M shares of Triangle stock at $18 per share, for a total of $118M; additionally, Abbott will provide research funding of $31.7M and up to $185M in milestones, plus will share future commercialization costs; companies will share profits and losses for all Triangle drug candidates, and Triangle will receive detailing fees and commissions on incremental sales generated for the Abbott products; Abbott will have right of 1st discussion on future Triangle compounds, and the partners plan to execute a manufacturing agreement to allow Abbott to produce certain Triangle products worldwide; Warburg Dillon Read acted as financial adviser to Triang
Unigene Laboratories Inc. Strakan Ltd. (UK) Forcaltonin injectable calcium for Paget's disease ND Strakan distributes product to hospitals and pharmacies in the UK and Ireland upon marketing authorization, paying royalties to Unigene (1/99)
Vivus Inc. Bio-Medic Institute Inc. (Japan) Agreement for registration and commercialization of Vivus' Muse (alprostadil; for erectile dysfunction) in Japan $5M Bio-Medic will make a $5M up-front payment to Vivus and assume responsibility for all clinical and regulatory activities necessary for registration of Muse in Japan; Vivus will manufacture and sell Muse to BioMedic (5/99)
Zonagen Inc. Schering-Plough Corp. Vasomax (phentolamine mesylate) for erectile dysfunction ND Schering-Plough exercises right to begin manufacturing product, which is under review by the FDA; further terms ND (2/99)